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Abstract Quenched phosphorescence was used, for the
first time, as detection mode in the chiral separation of
methotrexate (MTX) enantiomers by electrokinetic chro-
matography. The detection is based on dynamic quenching
of the strong emission of the phosphorophore 1-bromo-4-
naphthalene sulfonic acid (BrNS) by MTX under deoxy-
genated conditions. The use of a background electrolyte
with 3 mg/mL 2-hydroxypropyl-β-cyclodextrin and 20%
MeOH in 25 mM phosphate buffer (pH 7.0) and an applied
voltage of 30 kV allowed the separation of L-MTX and its
enantiomeric impurity D-MTX with sufficient resolution. In
the presence of 1 mM BrNS, a detection limit of 3.2×
10−7 M was achieved, about an order of magnitude better
than published techniques based on UV absorption. The
potential of the method was demonstrated with a degrada-
tion study and an enantiomeric purity assessment of L-
MTX. Furthermore, L-MTX was determined in a cell
culture extract as a proof-of-principle experiment to show
the applicability of the method to biological samples.
Keywords Capillary electrophoresis . Chiral analysis .
Cyclodextrin . Enantiomeric purity
Introduction
L-Methotrexate (L-MTX, amethopterin, (2S)-2-[[4-[(2,4-
diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]
pentanedioic acid) (Fig. 1) is an antimetabolite of folic acid
that is widely used for the treatment of several cancers,
including childhood leukemia, head and neck cancer, and
micrometastases of osteosarcoma. More recently, it is also
being used at low dose for the treatment of rheumatoid
arthritis, psoriasis, and steroid-dependent asthma [1–3].
L-MTX acts by inhibiting the enzyme dihydrofolate reductase
(i.e., disruption of folate biosynthesis) due to its greater
affinity for the enzyme than the closely related folic acid.
This means that in the presence of L-MTX, key reactions in
cell division are shut down [4]. The D-enantiomer (D-MTX) is
subject to significantly different pharmacokinetics; it has a
similar inhibitory effect on dihydrofolate reductase, but its
antitumor effect is reduced [1, 5]. For that reason, D-MTX has
to be considered as a chiral impurity of L-MTX; it can
originate from the synthesis of L-MTX or from racemization
during the shelf life of the pharmaceutical product under
improper storage conditions [6]. Regulatory requirements
regarding the purity of chiral drugs have generally become
stricter in recent years; therefore, the development of
analytical methodologies to test for enantiomeric impurities
in pharmaceutical formulations is of great importance.
Among the analytical techniques currently used for the
purity control of pharmaceuticals, electrokinetic chroma-
tography (EKC), a mode of capillary electrophoresis (CE),
was shown to be a powerful tool in the field of chiral
separations [7–17]. With UV absorption detection, which is
still used most often in CE, the concentration sensitivity is
limited by the optical path length of the capillary. For
compounds with a chromophoric group, concentration
limits in the micromolar range may be achieved in the
most favorable cases [18]. Such detection limits may not be
sufficiently low for biomedical samples or if low concen-
trations of enantiomeric impurities have to be detected.
Therefore, we set out to investigate whether luminescence
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methods (preferably without chemical derivatization) can
provide a suitable alternative.
Next to fluorescence detection, which is well estab-
lished in CE, room temperature phosphorescence (RTP)
in liquid deoxygenated solutions was shown to be an
attractive luminescence spectroscopic method for detec-
tion in CE [19–27]. Apart from direct phosphorescence,
where the analyte is excited by light of an appropriate
wavelength and phosphoresces itself, several indirect
phosphorescence modes can be distinguished. In one
sensitized mode, the analyte is excited and transfers its
excitation energy to a more strongly phosphorescent
acceptor added to the background electrolyte (BGE), after
which the emission of the latter is observed. That
approach was used in a previous paper on the enantiose-
paration and phosphorescence detection of bupropion
[27]. Alternatively, one can excite a donor reagent with
excellent absorption properties, which then transfers its
electronic energy to the analyte of which the emission is
detected [28]. Finally, in the quenched mode, a phospho-
rescent reagent is excited and its phosphorescence quan-
tum yield is reduced by a biomolecular quenching process
with an analyte molecule, which leads to negative peaks in
the electropherogram [20, 21, 29, 30]. Importantly, in the
latter mode, also non-phosphorescent analytes can be
detected, which is the case in this study. It should be
noted that quenched phosphorescence is different from the
indirect UV absorption mode, which is based on electro-
phoretic displacement of the BGE by the analytes.
Examination of the literature reveals that chiral
discrimination of MTX has been achieved by means of
different analytical techniques such as amperometric
biosensors [31], voltammetric methods [32], potentiomet-
ric membrane electrodes [1], TLC [33], HPLC [6, 34, 35],
and CE [5, 36–39]. In the case of CE, the chiral separation
of MTX and other compounds was carried out to evaluate
vancomycin [36], D-(+)-tubocurarine [37], and cyclo-
sophoraoses [39] as chiral selector. Moreover, Kuo et al.
[38] developed a method for the enantiomeric analysis of
MTX in pharmaceuticals using 2-hydroxypropyl-β-cyclo-
dextrin (HP-β-CD) as chiral selector. However, this
method was only applied to verify the content of L-MTX
in tablets and injection formulations, but not for purity
control. On the other hand, Gotti et al. [5] carried out the
determination of achiral and chiral impurities of L-MTX in
pharmaceuticals using a micellar EKC system with β-CD.
In this work, we explore the applicability of phospho-
rescence as detection mode for the chiral separation of
MTX by EKC. First, the direct and indirect phosphores-
cence properties of MTX were investigated in batch
experiments. The quenched phosphorescence mode was
found to be appropriate for the detection of MTX in
combination with its chiral separation. In addition, the
influence of different experimental conditions on the
enantiomeric separation was also studied. Finally, the
method developed in this work was applied to the
enantiomeric purity control of L-MTX in a pharmaceutical
formulation, to a short-term stability study, and to the
determination of L-MTX in a cell culture extract.
Material and methods
Reagents and samples
All reagents employed were of analytical quality. Sodium
phosphate monobasic, methanol, and β-CD were purchased
from Sigma (St. Louis, MO, USA). Sodium hydroxide was
obtained from Fluka (Buchs, Switzerland). (±)-Camphor-
quinone (CQ) and HP-β-CD were from Aldrich (Steinheim,
Germany). 1-Bromo-4-naphthalenesulfonic acid (BrNS)
was synthesized in-house [40]. Water used for preparing
the solutions was purified through a Milli-Q system from
Millipore (Bedford, MA, USA). L-MTX was obtained from
Aldrich (Steinheim, Germany), and D-MTX was kindly
provided by Dr. R. Gotti (University of Bologna, Italy). The
pharmaceutical formulation analyzed (Emthexate PF,
100 mg/mL; Pharmachemie BV, Haarlem, the Netherlands)
and the L-MTX containing cell culture extract were kindly
provided by Dr. G. Jansen and I. Kathman (VU Medical
Center, Amsterdam, the Netherlands).
Instrumentation
A Cary Eclipse Luminescence Spectrometer (Varian,
Melbourne, Australia) equipped with a pulsed Xe lamp
was used for the batch experiments. The samples were
deoxygenated using a stable nitrogen flow in a long-necked
cuvette with a stopper and narrow vent (Hellma, Müllheim,
Germany). The temperature was kept at 20 °C using the
single-cell Peltier Cooler of the spectrometer. The phos-
phorescent reagents BrNS and CQ were excited at 294 or
Fig. 1 Structure and pKa of L-methotrexate
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470 nm, respectively. Excitation and emission bandwidths
were set to 10 nm and the PMT voltage was 600 V. To
avoid detecting interfering scatter and fluorescence, a delay
time of 0.1 ms and a gate time of 5.0 ms were used. For the
lifetime measurements, the initial delay time and the gating
time were set at 0.05 ms. Decay curves were fitted in
OriginPro 8.
EKC separations were carried out using a CE system
(200 series) from Prince Technologies (Emmen, the
Netherlands) with an uncoated fused silica capillary of
75-μm i.d. (375-μm o.d.) and an effective length of
70 cm (total length 120 cm) from Polymicro (Phoenix,
AZ, USA). The measurements were made at room
temperature, the voltage applied was 30 kV, and the
samples were injected by pressure (50 mbar for
0.08 min). Since deoxygenation is required to observe
RTP, a modified vial was used to purge the buffer
solution continuously with nitrogen [19]. The nitrogen
flow rate was kept constant with a flow regulator. Before
first use, a new capillary was rinsed with 1 M NaOH for
30 min, followed by 2 min with Milli-Q water, 60 min
with the buffer, and 5 min with the BGE (purged with
nitrogen for at least 10 min before the start of the analysis
and during the separation to remove oxygen). Between
runs, the capillary was rinsed with BGE for 2 min.
An LS-40 Luminescence LC detector (Perkin-Elmer,
Beaconsfield, U.K.), adapted for CE [30], was used as
phosphorescence detection system. The delay time was
0.08 ms and the gating time 3.00 ms. Lamp excitation was
performed at 294 nm and emission was collected by means
of the total emission mirror and the 390-nm cutoff filter
provided with the instrument.
Analytical procedure
Running buffers were prepared by dissolving the appro-
priate amount of sodium phosphate in Milli-Q water,
adjusting the pH with 1 M NaOH before completing the
volume to get the desired buffer concentration (25 mM).
BGEs were prepared by dissolving the appropriate
amount of cyclodextrins in the buffer solution. Stock
solutions of 0.025 M BrNS and 0.1 M (±)-CQ were
prepared in water and MeOH, respectively, and stored at
5 °C. Stock solutions of L- or D-MTX were prepared by
dissolving the appropriate amount of each enantiomer in
0.1 M NaOH up to a final concentration of 10−3 M (stored
at −20 °C). Aliquots were diluted in water to get solutions
with the desired concentrations (using an L/D ratio of 2:1
for easy distinction of the two peaks).
Human CEM leukemia cells (5×106 CEM-WT) were
centrifuged (528×g for 5 min at room temperature), and the
pellet was washed with 20 mL (4 °C) Hanks balanced salt
solution (HBSS) buffer containing 20 mM HEPES,
140 mM NaCl, 6 mM KCl, 2 mM MgCl2, and 6 mM
glucose, pH 7.4, set with NaOH. After centrifugation
(528×g for 5 min at 4 °C), the pellet was resuspended in
1 mL HBSS (4 °C) followed by centrifugation (15,294×g
for 5 min at 4 °C). The pellet obtained was resuspended in
150 μL HBSS (4 °C) and spiked with 1 μM MTX and
40 μL ice-cold 40% trichloroacetic acid. After 20 min, the
cell suspension was shaken and centrifuged at 15,294×g for
5 min at 4 °C, and the supernatant was separated and
suspended in alamine/freon. Finally, the aqueous layer was
separated by centrifugation (15,294×g, 5 min, 4 °C) and
stored at −20 °C.
All BGEs, standards, and samples were filtered through
0.2-μm syringe filters (Whatman, Dassel, Germany) before
their use in the CE system.
Results and discussion
Batch experiments
According to the literature, the enantiomeric separation of
MTX by EKC can be achieved using HP-β-CD as chiral
selector in phosphate buffer at pH 7.0 [38]. Keeping in
mind that the objective of this work was to investigate the
feasibility of phosphorescence detection in CE as an
alternative to UV detection, we employed these preliminary
conditions to study the direct and indirect phosphorescence
of MTX in batch.
In order to find optimum excitation conditions, first of
all, the absorption and fluorescence spectra were
recorded. In UV–Vis absorption, four maxima can be
discerned, i.e., at 220, 259, 303, and 373 nm. Under the
experimental conditions, MTX was found to be weakly
fluorescent, too weak to be of interest from an analytical
detection point of view. Interestingly, in fluorescence
instead of a single emission spectrum—as generally
expected—two weak emission bands were found, i.e., at
356 and 465 nm (not shown). This is not due to the
presence of two species, but is attributed to the fact that
MTX is composed of two separate chromophoric
moieties, connected by an aliphatic –C–N– group. The
corresponding excitation spectra are distinctly different:
The maxima at 220 and 303 nm are associated with the
365-nm band; those at 259 and 373 nm with the 456-nm
band. Thus, there are two suitable excitation wavelengths
for MTX: 303 and 373 nm, corresponding presumably
with the benzoyl and the pteridin unit.
Also, two phosphorescence emission signals could be
expected, but under deoxygenated conditions, no direct
phosphorescence was observed at either excitation wave-
length (303 and 373 nm). Therefore, indirect phospho-
rescence in sensitized and quenched mode was explored.
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For this purpose, the phosphorophores BrNS and CQ
were tested; both compounds have been used extensively
in earlier studies [19, 21–23, 26, 28, 40, 41]. In the
sensitized phosphorescence mode, MTX, is excited and
transfers its excitation energy to BrNS or CQ, of which the
phosphorescence is then observed. When BrNS was used
as acceptor, MTX was only excited at 373 nm since
303 nm is too close to the maximum excitation wave-
length of BrNS (294 nm) and would thus result in a high
background from direct excited acceptor. In the case of
BrNS, sensitized phosphorescence was not observed. For
CQ, the energy transfer from MTX (excited at 303 or
373 nm) resulted in only a small increase in the CQ
phosphorescence signal (data not shown). Thus, we
concluded that also sensitized phosphorescence is not a
promising option for MTX detection. Presumably, for both
chromophoric moieties, the triplet state energies are too
low for efficient transfer to BrNS or CQ.
In the dynamically quenched mode, BrNS or CQ are
excited (at 294 or 470 nm, respectively), and their
phosphorescence intensity is monitored. If MTX has a
lower triplet state energy, the transfer of excitation energy
from the phosphorophore to MTX can take place, which
diminishes the observed phosphorescence intensity from I0
to I according to the Stern–Volmer equation:
I0=I ¼ 1þ kq Q½ t0 ð1Þ
where kq is the quenching rate constant, [Q] the analyte
concentration, and τ0 the triplet lifetime of the phosphor-
ophore in the absence of quenching analyte [29, 30].
Figure 2 shows the phosphorescence emission spectra
of BrNS and CQ, recorded in batch in the presence of HP-
β-CD, with and without 10−5 M L-MTX. In the absence of
quencher, the phosphorescence intensity of BrNS was
about 50 times higher than that of CQ. For both
phosphorophores, the presence of L-MTX resulted in a
decrease of the signal: I0/I=15.3 for BrNS and 1.5 for CQ.
Lifetime measurements showed that in both cases, we are
indeed dealing with dynamic quenching: For instance, for
BrNS, the phosphorescence lifetime decreased from 2.05
to 0.150 ms in the presence of MTX. This 14-fold
decrease is very close to the observed change in intensity.
The rate constant of quenching kq was calculated from
Eq. 1 as 7×108 M−1 s−1, close to the typical rate constant
of collisional quenching (1–5×109 M−1 s−1).
In dynamically quenched phosphorescence detection for
CE, a high background signal (with relatively low noise)
and a long triplet lifetime τ0 are preferred for maximum
sensitivity. Therefore, the quenched mode with BrNS was
selected for further experiments.
CE phosphorescence
For the optimization of the CE separation, we started out
from the experimental conditions described by Kuo et al.
[38] with small modifications, such as the use of a longer
capillary (at least 60 cm to the detection window instead of
30 cm since short capillary lengths are not practical with the
LS40 detector), a higher CE voltage (30 kV), and the
presence of 1 mM BrNS in the BGE. At first, only a partial
resolution of MTX enantiomers was obtained. Therefore,
various parameters such as CD concentration, methanol
(MeOH) percentage, and capillary length were studied in
order to improve the chiral separation. These aspects were
optimized as separate parameters.
The influence of the concentration of HP-β-CD on the
enantioseparation of MTX was investigated in the range
from 1 to 10 mg/mL because the degree of complexation of
the enantiomers is affected by the concentration of the
chiral selector. The resolution gradually deteriorated when
the concentration increased up to 10 mg/mL. In addition, an
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Fig. 2 Phosphorescence emission spectra of 10−5 M BrNS (a) and
2 mM (±)-CQ (b) with and without quenching by L-MTX (10−5 M) in
25 mM phosphate buffer (pH 7.0) with 3 mg/mL HP-β-CD. Batch
measurements: spectrometer settings—delay time, 0.1 ms; gating time,
5.0 ms; λexc=294 nm for BrNS and 470 nm for (±)-CQ; excitation and
emission band widths, 10 nm. All samples were purged with nitrogen
to remove oxygen
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increase in the CD concentration resulted in shorter
migration times. Because of the lower electrophoretic
mobility of the inclusion MTX/HP-β-CD complexes in
comparison with the free analyte, the complexes migrate
closer to the EOF. Eventually, 3 mg/mL of HP-β-CD was
chosen for further experiments as a compromise between
resolution and analysis time. Interestingly, the peak areas
observed with quenched phosphorescence detection were
hardly affected by the HP-β-CD concentration, indicating
that free and complexed MTX have similar quenching
properties toward BrNS.
Since the CD concentration could not improve the
separation further, the addition of different percentages of
MeOH (10%, 20%, and 25%) was studied. Adding organic
modifier to the running buffer may affect the enantiomeric
resolution, as well as other parameters such as the EOF, the
conductivity of the BGE, and the analysis time. With higher
percentages of MeOH, the chiral resolution improved, but
this added to the analysis time. Twenty percent MeOH was
chosen as a trade-off between both parameters. However,
the enantioseparation of MTX was still only partial. We
hypothesized that the 6-mm detection window of the lamp-
based phosphorescence detector could contribute to the
overall band broadening. The detection window was
reduced in size by means of black shrink tubing around
the capillary. Figure 3 shows the electropherograms
obtained for a solution of 5×10−6 M L-MTX and 2.5×
10−6 M D-MTX using different detection window lengths.
Reducing the window to about 2 mm improved the
resolution, but with even narrower detection windows, a
significant loss of signal (I0/I) was observed. As a
compromise, the 2-mm window was chosen for further
experiments. The capillary length was increased (from 60 to
70 cm) to further improve the separation. Finally, in order
to find the optimal BrNS concentration and obtain the
highest phosphorescence intensity, it was varied from 0.5 to
1.5 mM, but no major differences were observed. Since the
use of 1 mM BrNS resulted in a slightly higher phospho-
rescence intensity, it was chosen as the best BrNS
concentration (data not shown).
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Fig. 3 EKC phosphorescence: influence of the detection window
length on the phosphorescence intensity and chiral resolution of D,L-
MTX. Sample, 5×10−6 M L-MTX+2.5×10−6 M D-MTX; BGE, 1 mM
BrNS with 3 mg/mL HP-β-CD and 20% MeOH in 25 mM phosphate
(pH 7.0); untreated fused-silica capillary, 110 cm (60 cm to the
detector window)×75-μm i.d. Other conditions are described in the
experimental section. The BGE was purged with nitrogen to remove
oxygen. The electropherograms are vertically shifted for clarity
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Fig. 4 D-MTX impurity determination in a standard sample (top) and
in a pharmaceutical formulation (bottom); unspiked samples with a
nominal L-MTX concentration of 1×10−4 M. Untreated fused silica
capillary, 120 cm (70 cm to the detector window)×75-μm i.d. Other
conditions as in Fig. 3. The electropherograms are vertically shifted
for clarity
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Fig. 5 EKC phosphorescence of L-MTX (1 μM) in a cell culture
extract. Experimental conditions as in Fig. 4
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In summary, the chiral separation of MTX enantiomers
with quenched phosphorescence detection was achieved
using as BGE 1 mM BrNS with 3 mg/mL HP-β-CD and
20% MeOH in 25 mM phosphate buffer (pH 7.0) in a
capillary of 70 cm to the detector (with a detection window
of about 2 mm). These conditions allowed the separation of
MTX with a resolution of ~1.5. Finally, the LOD and LOQ
were calculated from the S/N ratio equal to 3 and 10,
respectively, when injecting a solution of 2.5×10−6 M L-
MTX and 1.25×10−6 M D-MTX. A LOD of 3.2×10−7 M
and a LOQ of 1.1×10−6 M were achieved for both
enantiomers. This is a major improvement compared with
the LODs reported in the literature for the chiral separation
of MTX with UV absorption detection: 4×10−6 M for CE
[38], 1.5×10−6 M for MECK [5], and 2×10−6 M for HPLC
[6].
Application to formulations and biological samples
The developed method was applied to determine the optical
purity of standards and a pharmaceutical formulation of L-
MTX. The level of D-MTX in both samples was quantified
by means of the standard addition method. The percentages
of spiked D-MTX ranged from 0% to 3% (w/w), relative to
a nominal concentration of L-MTX of 10−4 M. The actual
level of the L-enantiomer was too high to be determined
immediately (upper limit of the calibration range is 1×
10−5 M) and was therefore verified separately after dilution.
In a quenching experiment, the peak heights do not
increase linearly with the analyte concentration. Linear
calibration curves were obtained by plotting I0/I, according
to the Stern–Volmer equation (Eq. 1), versus the percentage
of D-MTX (X) added to the sample. The equations
obtained, by means of a linear regression analysis, were:
y=0.228x+1.248 (r2=0.9994) for the standard and y=
0.249x+1.148 (r2=0.9899) for the pharmaceutical formu-
lation. Figure 4 shows the electropherograms obtained for
both samples when 0% D-MTX was added. Percentages of
1.1% (chemical standard) and 0.6% D-MTX (pharmaceuti-
cal formulation) were calculated by solving the above
equations for y=1.
A short-term degradation study was also carried out to
investigate the possible racemization of L-MTX. Nine
standard samples of 10−4 M L-MTX were stored at 4, 20,
and 37 °C and analyzed after 2, 6, and 24 h. The D-MTX
levels were very similar in all samples (the ratios I0/I ranged
from 1.30 to 1.36), which showed that no significant
racemization of L-MTX occurred under the conditions
studied.
Finally, as a proof-of-principle experiment for the applica-
tion of the developed method to biological samples, L-MTX
was determined in a cell culture extract from human CEM
leukemia cells. The extract was spiked with 1 μM L-MTX, a
realistic level in pharmacokinetic and pharmacodynamic
experiments. As demonstrated in Fig. 5, the intracellular
components caused little interference in the quenched
phosphorescence detection of L-MTX. The L-MTX peak
was above the LOD level of 3.1×10−7 M (based on the
noise level measured over the range 5–10 min), but for
proper quantitation, slightly higher levels or sample
preconcentration would be preferred. The developed
method will be useful for determining the intracellular
concentration of MTX and can be applied in future studies
on the dynamic equilibrium between influx and efflux
routes.
Concluding remarks
Following the batch study of the phosphorescence
characteristics of MTX (direct and indirect phosphores-
cence), the quenched phosphorescence mode was chosen
as the detection method for the chiral separation of MTX
enantiomers by EKC. Under the optimized conditions,
1 mM BrNS with 3 mg/mL HP-β-CD and 20% MeOH
in 25 mM phosphate buffer (pH 7.0), the enantiomeric
separation of L- and D-MTX was obtained with a
resolution ~1.5. Under these conditions, a LOD of 3.2×
10−7 M was achieved for both enantiomers, improving the
LODs previously reported in the literature with about an
order of magnitude. Finally, the developed method was
satisfactorily applied to the enantiomeric purity control of
standards and a pharmaceutical formulation. A short-term
stability study did not show any major degree of
racemization in aqueous solution up to 24 h, not even at
37 °C. The method was also found to be suitable for
studying MTX in cell culture extracts.
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